SCHEMBL25530484

SCHEMBL25530484

C=CC(O)NCCc1nnc(-c2ccccc2Nc2ccc(C(F)(F)F)cc2)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 4/20 0.38
KDR P35968 4/20 0.38
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
GSK3B P49841 2/20 0.36
DDX3X O00571 1/20 0.35
TAS2R14 Q9NYV8 1/20 0.34
TP53 P04637 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
SUCNR1 Q9BXA5 1/20 0.32
KCNH3 Q9ULD8 1/20 0.31
MAPK8 P45983 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22571451 0.90 KDM4E (0.38) FLT1KDRKDM4EALDH1A1CYP1A2
SCHEMBL22556548 0.85 FLT1 (0.41) FLT1KDRKDM4EALDH1A1CYP1A2
SCHEMBL30463765 0.85 FLT1 (0.41) FLT1KDRKDM4EALDH1A1CYP1A2
SCHEMBL22556459 0.83 DDX3X (0.41) FLT1KDRKDM4EALDH1A1CYP1A2
SCHEMBL22556449 0.82 FLT1 (0.42) FLT1KDRKDM4EALDH1A1CYP1A2
SCHEMBL30463791 0.82 FLT1 (0.42) FLT1KDRKDM4EALDH1A1CYP1A2
SCHEMBL30463786 0.82 FLT1 (0.43) FLT1KDRKDM4EALDH1A1CYP1A2
SCHEMBL22556577 0.82 FLT1 (0.43) FLT1KDRKDM4EALDH1A1CYP1A2
SCHEMBL22556372 0.82 FLT1 (0.44) FLT1KDRKDM4EALDH1A1CYP1A2
SCHEMBL22556452 0.81 DDX3X (0.43) FLT1KDRKDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 FLT1 2445/4885KDR 1811/4885KDM4E 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.